CURRENTLY ENROLLING
Dextenza PTX – (Phase IV)
Pre-surgical ocular surface treatment with intracanalicular dexamethasone insert to assess the effect on intraocular lens measurements and refractive outcomes.
Dim Light Vision Disturbance – (Phase III)
Randomized, placebo-controlled, double-masked, multiple-dose study of the safety and efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in subjects with dim light vision disturbances (DLD).
PREVIOUSLY ENROLLED
2019
A pre-cataract complimentary treatment of Lipiflow to monitor the effects of the procedure on pre-cataract surgery measurements for patients who have selected a Symfony or Symfony Toric implant. (Tahoe; Johnson & Johnson)
2019
An external pain-free neuro-stimulator that takes approximately 30 seconds is applied to each side of the bridge of the nose to stimulate the lacrimal nerve to produce natural tears to help patients who suffer from dry eye disease. The device will be provided to the patient at no charge for the 90-day study period. (Olympic)
2018
Surface analysis to measure improvement with single use of Bruder Mask treatment. (Bruder Health Care)
2018
Evaluate the tolerability of treatment with Klarity-C ophthalmic solution for Dry Eye Disease. (Imprimis Therapeutics)
2018
Phase 3 controlled study, double masked to compare efficacy and treatment standards in patients with dry eye disease. (Kala Pharmaceutical)
2017
Post-approval study evaluating the rates of visual distortions for the TECNIS Toric IOLs with >2.0D of cylinder correction at the corneal plane in a larger population compared to a non-toric IOL and to ensure the continued safety of approved devices. (Johnson & Johnson)
2017
Phase 3 clinical trial evaluating safety and efficacy of steroid delivery through iontopheresis in patients with non-infectious anterior segment uveitis. (EyeGate)
2017
Tracking the time and percentage of recovery with prescribed NSAIDs. (Bausch & Lomb)
2016
ICON C-1501: Dexamethasone intracameral steroid suspension for the treatment of post operative inflammation. (ICON)
2016
Glaukos GC-007: To evaluate the safety and efficacy of the Glaukos Suprachoroidal Stent Model G3 in conjunction with cataract surgery compared to cataract surgery only in subjects with mild to moderate open-angle glaucoma. (Johnson & Johnson)
2016
PRN: Effect of Omega 3 oral supplement on keratometry
2016
ReSure Sealant in cataract surgery: Ocular Therapeutics
2016
The percentage of Malyugin Ring and surgical time use with Omidria compared to BSS with Epinephrine during cataract surgery
2016
Abbott post-approval study to evaluate rate of residual visual distortions with corneal astigmatism lens correction
2015
Safety and efficacy of OTXDP in post-op pain and inflammation in cataract surgery (Ocular Therapeutix)
2015
Comparison of the safety and efficacy of Ta4 to placebo for the treatment of neurotrophic keratits (ORA)
2015
A registry evaluation of ReSure® Sealant for specified adverse ocular events after sealing corneal incisions in patients undergoing clear cataract surgery (Ocular Therapeutix)
2015
Investigation of trabecular micro-bypass stent system in conjunction with cataract surgery (Glaukos)
2014
A Phase 3, Multi-Center, Double-Masked, Placibo-Controlled, Randomized Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placibo in Subjects with Dry Eye and History of Artificial Tear Use (Shire)
2014
Functional Benefit of the AcrySof Natural Chromophore post-market study (Alcon)
2014
Lenstec HD and HDO IOLs with Monte Carlo Application
2014
IPL Study with Duke Eye Center
2014
Abbott Medical Optics Tecnis Toric 1-piece IOL registry
2014
Ocular Theraputix evaluation of ReSure® Sealant in high risk patients
2014
Bausch + Lomb Lotemax loteprednol etabonate ophthalmic suspension ophthalmic gel versus vehicle gel in treatment of inflammation/pain following cataract surgery
2014
Abbott Medical Optics use of WHITESTAR Signature® with two different tips in cataract surgery
2014
Hoffer H5 Axial Length
2014
Icon Phase 3 Treatment of Post-Op Inflammation in Cataract Study
2014
Physician Recommended Nutriceuticals Dry Eye Study
2013
Alcon Research Ltd, Effect of blue light filtration on visual performance, protocol A01311 version 1.0
2013
Lenstec HDO IOL analyzing Dysphotopsia in Pseudophakic patients
2013
Adenovirus Rapid Pathogen Screening Study
2013
SONATA, a Phase III, multi-center, randomized, double-masked and placebo-controlled study evaluating the safety of a 5.0% concentration of Lifitegrast Ophthalmic Solution compared to placebo in subjects with dry eye
2013
Impact of tear osmolarity on pre-surgical calculations in cataract surgery
2013
The influence of the PRN Dry Eye Omega 3 nutritional regimen in osmolarity in cases of occasional dry eye.
2013
Sarcode Bioscience, Inc., Sonata Clinical Trial, Dry Eye
2013
Internal study on Restasis® Cyclosporine Ophthalmic Emulsion BID alone, with Lotemax induction, and with Bromday induction
2012
Mixing and matching a toric IOL in the eye with the greater astigmatism and using a blended min-mono approach with an aspheric mono-focal IOL plus an LRI to correct the spherical and cylinder errors in the eye with the lesser astigmatism.
2012
Conversion rates for premium services (LRI, Toric and presbyopia correcting IOLs) based on gender and age.
2012
The use of an equibiconvex quarter diopter aspheric IOL for cataract surgery to measure uncorrected intermediate vision.
2011
Alcon Pharmaceuticals – Difluprednate Ophthalmic Emulsion 0.05% for post operative inflammation and pain QID vs. BID when paired with an NSAID
2011
Abbot Medical Optics — Evaluation of RevitaLens for soft contact lens care
2010
Abbot Medical Optics – Evaluation of Blink Artificial Tears on its effectiveness for the symptoms of dry eye syndrome
2010
Ista Pharmaceuticals – 6 Month Dry Eye Study
2009
Sanofi-Aventis – Providing ophthalmologic evaluations for a study in which Tamaris, a vascular endothelial growth factor, is being used to help peripheral blood vessels. The study requires dilated ophthalmic funduscopic exams to participants on scheduled intervals.
2009
Ista Pharmaceuticals — Efficacy and Safety of Bromfenac Ophthalmic Solution QD vs. Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery
2008
Allergan, Inc. – Phase IV – A Multi-Center, investigator-masked, randomzed, parallel study to compare the IOP lowering efficacy and safety of Combigan (fixed combination of 0.2% Brimonidine Tartrte and 0.5% Timolol Maleate) with Timolol (0.5% Timolol Maleate), when each is used as adjunctive therapy to Xalatan (0.005% Latanoprost) in subjects with Open-Angle Glaucoma and Ocular Hypertension.
2008
Ista Pharmaceuticals – Phase II – A Multi-Center, Double Blind, Vehicle-Controlled, Randomized Study of Ecabet Ophthalmic Solution in Patients with Dry Eye Disease
2007
Allergan, Inc. – Phase IV – A Multicenter, Masked Evaluation of Ocular Surface Tolerability Associated with Bimatoprost 0.03%, Travoprost 0.004% (BAK free) or Latanoprost 0.005% Therapy in Patients with Glaucoma or Ocular Hypertension.
2005 – 2006
Alcon Pharmaceutical, Travatan dosing aid study
2004
Wills Eye Hospital – Internet Based Study, Is One of Two Topical Prostaglandin Analogues Significantly More Tolerable Than the Other: Bimatroprost v. Latanoprost?